CELLECTIS (ALCLS.PA) Stock Fundamental Analysis
Europe • Euronext Paris • EPA:ALCLS • FR0010425595
3.265 EUR
-0.15 (-4.53%)
Last: Jan 29, 2026, 07:00 PM
ALCLS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 85 industry peers in the Biotechnology industry. ALCLS has a bad profitability rating. Also its financial health evaluation is rather negative. ALCLS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- ALCLS had negative earnings in the past year.
- ALCLS had a negative operating cash flow in the past year.
- In the past 5 years ALCLS always reported negative net income.
- In the past 5 years ALCLS reported 4 times negative operating cash flow.
1.2 Ratios
- ALCLS has a Return On Assets of -28.25%. This is comparable to the rest of the industry: ALCLS outperforms 49.41% of its industry peers.
- ALCLS has a Return On Equity (-102.97%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.25% | ||
| ROE | -102.97% | ||
| ROIC | N/A |
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With a Gross Margin value of 3.66%, ALCLS is not doing good in the industry: 62.35% of the companies in the same industry are doing better.
- ALCLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 3.66% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ALCLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, ALCLS has more shares outstanding
- Compared to 5 years ago, ALCLS has more shares outstanding
- ALCLS has a better debt/assets ratio than last year.
2.2 Solvency
- ALCLS has an Altman-Z score of -0.48. This is a bad value and indicates that ALCLS is not financially healthy and even has some risk of bankruptcy.
- ALCLS's Altman-Z score of -0.48 is in line compared to the rest of the industry. ALCLS outperforms 47.06% of its industry peers.
- ALCLS has a Debt/Equity ratio of 0.91. This is a neutral value indicating ALCLS is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.91, ALCLS is in line with its industry, outperforming 42.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.91 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.48 |
ROIC/WACCN/A
WACC6.47%
2.3 Liquidity
- A Current Ratio of 1.38 indicates that ALCLS should not have too much problems paying its short term obligations.
- ALCLS's Current ratio of 1.38 is on the low side compared to the rest of the industry. ALCLS is outperformed by 64.71% of its industry peers.
- ALCLS has a Quick Ratio of 1.38. This is a normal value and indicates that ALCLS is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of ALCLS (1.38) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.38 |
3. Growth
3.1 Past
- ALCLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.80%, which is quite impressive.
- The Revenue has grown by 154.92% in the past year. This is a very strong growth!
- ALCLS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.44% yearly.
EPS 1Y (TTM)70.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.35%
Revenue 1Y (TTM)154.92%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%105.89%
3.2 Future
- The Earnings Per Share is expected to decrease by -54.16% on average over the next years. This is quite bad
- Based on estimates for the next years, ALCLS will show a very strong growth in Revenue. The Revenue will grow by 25.15% on average per year.
EPS Next Y-166.15%
EPS Next 2Y-83.7%
EPS Next 3Y-54.16%
EPS Next 5YN/A
Revenue Next Year45.52%
Revenue Next 2Y32.52%
Revenue Next 3Y9.94%
Revenue Next 5Y25.15%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ALCLS. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALCLS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ALCLS's earnings are expected to decrease with -54.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-83.7%
EPS Next 3Y-54.16%
5. Dividend
5.1 Amount
- No dividends for ALCLS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CELLECTIS / ALCLS.PA FAQ
Can you provide the ChartMill fundamental rating for CELLECTIS?
ChartMill assigns a fundamental rating of 2 / 10 to ALCLS.PA.
What is the valuation status of CELLECTIS (ALCLS.PA) stock?
ChartMill assigns a valuation rating of 0 / 10 to CELLECTIS (ALCLS.PA). This can be considered as Overvalued.
What is the profitability of ALCLS stock?
CELLECTIS (ALCLS.PA) has a profitability rating of 1 / 10.
Can you provide the financial health for ALCLS stock?
The financial health rating of CELLECTIS (ALCLS.PA) is 2 / 10.
What is the expected EPS growth for CELLECTIS (ALCLS.PA) stock?
The Earnings per Share (EPS) of CELLECTIS (ALCLS.PA) is expected to decline by -166.15% in the next year.